Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharma CS (NQ: MRNS )

1.330 +0.030 (+2.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,305,323
Open 1.310
Bid (Size) 1.330 (1)
Ask (Size) 1.360 (31)
Prev. Close 1.300
Today's Range 1.300 - 1.380
52wk Range 1.110 - 11.26
Shares Outstanding 54,933,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
From Marinus Pharmaceuticals
Via Business Wire
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q1 2024
MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-87.21%
-87.21%
1 Month
-7.64%
-7.64%
3 Month
-86.65%
-86.65%
6 Month
-78.44%
-78.44%
1 Year
-83.64%
-83.64%

More News

Read More
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Unveiling 10 Analyst Insights On Marinus Pharma
Via Benzinga
How Is The Market Feeling About Marinus Pharma?
Via Benzinga
The Latest Analyst Ratings For Marinus Pharma
Via Benzinga
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
From Marinus Pharmaceuticals
Via Business Wire
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss
Via Benzinga
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
Via Benzinga
Topics Stocks
Exposures US Equities
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Are Stocks Up Today?
Via InvestorPlace
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
DJT Stock Alert: Trump Media Plunges on Share Sale Panic
Via InvestorPlace
Topics Government
Exposures Political
Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?
Via InvestorPlace
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?
Via Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.